Stock of the week: REVA rally looms large with news flow imminent
Published 21-SEP-2018 11:56 A.M.
9 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Not only is REVA Medical, Inc. (ASX:RVA) Finfeed’s stock of the week, but it could well be the ASX’s stock of the month depending on what unfolds in the coming days when it presents new data on its proven medical products to a global audience.
REVA is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications.
In the last week, the company’s shares have increased more than 30% from 20.5 cents to 27 cents.
However, they still appear to be underdone, coming off an arguably oversold base which formed in June possibly on the back of tax loss selling.
Any news flow that has occurred in the last three months has been positive, resulting in some brief but substantial rallies.
In the latter part of July, REVA’s shares surged 50% under the second-highest volumes recorded by the company during its seven year history as a listed entity.
The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.
Save this date
Should findings due to be released in coming days result in the company’s shares gathering momentum, a sustained recovery may be on the cards.
However, this remains a speculative stock and investors should seek professional financial advice if considering this stock for your portfolio.
REVA is delivering a presentation to industry leaders in its field at the Transcatheter Cardiovascular Therapeutics (TCT) Conference, being held between September 21 and September 25 in San Diego, California.
The company’s scheduled presentations will also include two-year results from the FANTOM II trial that were previously presented at the EuroPCR conference held in Paris, France in May.
Importantly, REVA will present new data on the Fantom bioresorbable scaffold from its pilot study in patients with a specific type of heart attack called ST-segment elevated myocardial infarction.
Analysts at Morgans summed up their take on the company’s prospects in saying, “Growing sales, along with an expanding product offering, broadening applications of its novel polymer technology, favourable clinical data sets and numerous upcoming catalysts, should help to re-ignite investor interest.”
The broker has an add recommendation on the company with a valuation and price target of 66 cents, implying upside of nearly 150% to yesterday’s closing price.
Patients experiencing heart attacks account for between 30% and 40% of the percutaneous coronary intervention (PCI) patient population, and PCI is performed to restore blood flow to the heart.
While these patients are at a higher risk than stable patients, the characteristics of their arterial lesions are typically well suited to bioresorbable scaffolds.
Targeting the coronary artery disease market
REVA’s products target the coronary artery disease market (CAD), the most common type of heart disease.
Cardiovascular disease is the leading cause of death globally, and CAD treatments aim to restore blood flow through the blocked artery.
The company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds.
REVA is currently selling Fantom in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxemburg, Italy, and Turkey.
While listed on the ASX, REVA is based in San Diego, California, and employs more than 50 people in the US and Europe.
However, more important than where the company is domiciled, is its ability to expand into global markets.
The group has a strong track record of introducing its products into new regions as evidenced by the numerous European countries which have adopted its Fantom product.
REVA’s entry into new markets appears to have gained significant traction in 2018, and should the imminent news release regarding product progress be favourable this could potentially lead to an acceleration of its global expansion.
We have the technology
Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as alternatives to metallic stents for the treatment of coronary artery disease.
While the technological description sounds complex, the product and its applications are relatively easy to understand.
Scaffolds provide restoration of blood flow, support the artery through the healing process and then disappear or resorb from the body over a period of time.
This resorption is intended to allow the return of natural function of the artery with the aim of reducing the risk of adverse events associated with a permanent metallic implant.
Fantom and Fantom Encore are the only coronary bioresorbable scaffolds made from Tyrocore, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications.
Tyrocore is inherently radiopaque, making Fantom and Fantom Encore visible under x-ray fluoroscopy.
Fantom and Fantom Encore are designed with thin struts while maintaining strength, as well as possessing distinct ease-of-use features such as x-ray visibility and expansion with one continuous inflation.
Impressive second quarter
REVA made substantial inroads in the June quarter, delivering on many milestones that it had outlined earlier in the year which were aimed at driving commercial growth and expanding the use of Fantom.
The company entered its first distribution partnership to expand the use of Fantom to Turkey, presented new two-year clinical results from the FANTOM II trial, initiated a post market trial, and secured CE Mark for the full Fantom Encore product line.
As a result, REVA is continuing to see growth in product shipments and reorders, which is one of management’s most important metrics of commercial momentum.
The company completed on-boarding and training of its direct sales force in Germany, Switzerland, and Austria during the second quarter of 2018.
Additionally, REVA began its planned geographic expansion of Fantom by entering into a first commercial distribution partnership with Kardionet in Turkey.
In July 2018, REVA announced a second commercial distribution partnership with Bio Vascular Group in Italy and hired a part-time consultant to support direct sales in Belgium, the Netherlands and Luxembourg.
Product results do the talking
During the second quarter of 2018, REVA released two-year data from the FANTOM II trial at the EuroPCR conference in Paris, demonstrating sustained safety and efficacy of Fantom.
The results included a low 5.0% rate of major adverse cardiac events (MACE) in 240 patients.
MACE is a stringent definition of safety and efficacy combining all events related to cardiac death, myocardial infarction, and target lesion revascularization.
The endpoint of target lesion failure (TLF) is similar to MACE but only includes myocardial infarction events that are related to the treated vessel.
Importantly, the two-year TLF rate from 240 patients in the FANTOM II trial was 4.6%.
REVA highlighted that this compared favourably with the two-year TLF rates for to other products, Absorb (11.0%) and Xience (7.9%) in the 2,008-patient ABSORB III trial.
During the second quarter of 2018, REVA also initiated the Fantom post market trial in Europe.
The first patient was enrolled in May and the company is working to add new hospitals to the study.
REVA is targeting an enrolment of 1,500 patients at 50 to 100 hospitals in the post market trial.
Fantom Encore has thinner struts
In June 2018, REVA obtained CE Mark for the full Fantom Encore product line.
Fantom Encore, like Fantom, is used for the treatment of coronary artery disease.
The approval includes Fantom Encore in the 3.0 and 3.5 millimetre diameters, expanding the approved product line beyond the 2.5 millimetre diameter scaffold which was approved in February 2018.
The Fantom Encore product line has thinner struts than Fantom.
Reduction in strut thickness is associated with improved outcomes and ease-of-use, which are critical for broader adoption of bioresorbable scaffolds.
REVA plans to launch the Fantom Encore product line later this year.
Strong second-quarter revenue growth
REVA recognized $91,000 of net revenue during the three months ended June 30, 2018 compared to zero revenue for the same period in 2017.
Net revenue during the three months ended June 30, 2018 grew by 72% as compared to net revenue during the three months ended March 31, 2018, due to an increase in estimated customer usage.
Total product shipments for the three months ended June 30, 2018 were $149,000, a 16% increase as compared to total product shipments for the three months ended March 31, 2018.
Additionally, the company saw a 38% increase in the total number of customers as of June 30, 2018 versus March 31, 2018.
Morgans analyst Derek Jellinek was impressed with the company’s June quarter performance, in particular the 72% increase in revenue.
He continues to view Fantom and Fantom Encore as differentiated, best in class products and this is supported his ‘add’ recommendation and upbeat outlook statement as he said, “Sales momentum looks set to accelerate, with five fully trained reps (targeting Germany, Switzerland and Austria), recently inked distributorships in Turkey and Italy, and a growing product offering, with third-generation scaffold Fantom Encore recently obtaining CE Mark and slated to launch later this year.”
This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.